Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity

Inclusion criteria

• Premenopausal women 18 to 49 years of age are eligible for enrollment
• Patients have operable stage I to IIIA breast cancer for which treatment with adjuvant or neoadjuvant cyclophosphamide-containing chemotherapy was planned.
• Eligible participants had taken no estrogens, antiestrogens, selective estrogen-receptor modulators, aromatase inhibitors, or hormonal contraceptives within the month before enrollment.
• Human chorionic gonadotropin negative by urine test before entering the group.
• Informed consent, understanding and compliance with the requirements of the study.
• No significant chronic disease and any organ dysfunction.

Exclusion criteria

• Exceptions were made for the use of hormonal contraception in women younger than 35 years of age that was discontinued before randomization.
• Use of hormonal treatment for up to 2 months for the purposes of in vitro fertilization and cryopreservation of embryos or oocytes before randomization.
• Patients with metastatic lesions or history of bilateral ovariectomy,ovarian radiation were excluded.
• Patients received previous adjuvant endocrine therapy for breast cancer are not suitable to this trial.
• Patients with uterine and/or adnexal diseases needing medical or surgical treatment are not suitable.
• Allergic to active or inactive excipients of GnRHa is an exclusion criterion.